Early Detection of Subclinical Visual Damage After Blast-Mediated TBI Enables Prevention of Chronic Visual Deficit by Treatment With P7C3-S243
Investigative Ophthalmology & Visual Science2014Vol. 55(12), pp. 8330–8341
Citations Over TimeTop 10% of 2014 papers
Laura M. Dutca, Steven F. Stasheff, Adam Hedberg‐Buenz, Danielle S. Rudd, Nitya Batra, Frederick Blodi, Matthew S. Yorek, Terry C. Yin, Malini Shankar, Judith A. Herlein, J. Naidoo, L L Morlock, N Williams, Randy H. Kardon, Michael G. Anderson, Andrew A. Pieper, Matthew M. Harper
Abstract
Provocative PERG testing serves as a noninvasive test in the living organism to identify early damage to the visual system, which may reflect corresponding damage in the brain that is not otherwise detectable by noninvasive means. This provides the basis for developing an earlier diagnostic test to identify patients at risk for developing chronic CNS and visual system damage after TBI at an earlier stage when treatments may be more effective in preventing these sequelae. In addition, treatment with the neuroprotective agent P7C3-S243 after TBI protects from visual system dysfunction after TBI.
Related Papers
- → Neuroprotective effects of the survival promoting peptide Y-P30(2009)8 cited
- → Subclinical Hypothyroidism(2010)3 cited
- → Overt and Subclinical Hyperthyroidism Are Associated with Increased Mortality Whereas Subclinical Hypothyroidism Is Associated with Decreased Mortality(2014)
- STUDY ON THE RELATIONSHIP BETWEEN SUBCLINICAL EPILEPTIFORM DISCHARGE AND TCI(2002)
- Variations of lipids in patients with subclinical hypothyroidism(2009)